Details:
Adge has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analog which has demonstrated efficacy and safety in multiple Phase 2 clinical trials.
Lead Product(s): Elocalcitol
Therapeutic Area: Genetic Disease Product Name: RO269228
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Adge Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 25, 2022
Details:
43% increase in ratio of glycosylated alpha-dystroglycan to total αDG from baseline were measured for BBP-418, across all three dosing cohorts, signifying the oral therapy has potential to address both the root cause of LGMD2i and drive functional improvements for patients.
Lead Product(s): Ribitol
Therapeutic Area: Genetic Disease Product Name: BBP-418
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022